Abstract
Background
Entry into a new therapeutic area, that is, one in which a pharmaceutical firm lacks experience, is a considerable challenge for firms that need to overcome scientific and technological barriers. To address this issue, the present study aims to explore the potentiality of alliances in an empirical manner.
Methods
From the clinical trials sponsored by 20 major pharmaceutical firms during 2008–2016 listed at ClinicalTrials.gov (n = 14,941 clinical trials), cases of entering a new therapeutic area for a pharmaceutical firm were extracted (n = 73), followed by statistical analyses to evaluate the effect of alliances in this regard.
Results
We found that the average number of participating organizations in the cases of entering a new therapeutic area was significantly larger than that in the cases of entering an area in which firms had experience (P < .01), suggesting that alliance has a positive effect on new therapeutic entry for these pharmaceutical firms. Second, we found that the cases of partnering with nonindustrial or nongovernmental organizations (ie, universities, research institutes, hospitals, funding agencies, and others; n = 32 of the 73) were significantly associated with these new entry trials (adjusted odds ratio = 1.1, P < .05). Furthermore, we identified that 10 of the 32 clinical trials were associated with rare diseases, which is an overrepresentation compared to the occurrence in the universe (1015 of the 14,941; P < 10–5).
Conclusions
These findings strongly suggest the importance of alliances with diversified partners in new therapeutic entry and also provide a basis for further detailed investigation of key success factors for pharmaceutical firms.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Kessel M. The problems with today’s pharmaceutical business—an outsider’s view. Nat Biotechnol. 2011;29(1):27–33.
Fernald KDS, Weenen TC, Sibley KJ, Claassen E. Limits of biotechnological innovation. Technol Invest. 2013;4(3):168–178.
DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003; 22(2):151–185.
Schuhmacher A, Gassmann O, Hinder M. Changing R&D models in research-based pharmaceutical companies. J Transl Med. 2016; 14(1):105.
Behnke N, Retterath M, van Biesen T. Biopharma strategies: to outperform in pharma, go deep—not broad. In Vivo (Brooklyn). https://invivo.pharmaintelligence.informa.com/IV004544/To-Outperform-In-Pharma-Go-Deep-Not-Broad. Published 2016. Accessed March 19, 2018.
Mitchell P. Biogen Idec restructures, sharpens neurology focus. Nat Biotechnol. 2011;29(1):7–8.
Davie JM. Biogen and immune disease. Nature. 1999; 402(6763):48.
Gilead Sciences to acquire Kite Pharma for $11.9 billion. Gilead Sciences, Inc. http://www.gilead.com/news/press-releases/2017/8/gilead-sciences-to-acquire-kite-pharma-for-119-billion. Published August 28, 2017. Accessed March 19, 2018.
Dogramatzis D. Healthcare Biotechnology: A Practical Guide. 1st ed. Boca Raton, FL: CRC Press; 2010.
McAfee RP, Hugo M, Mialon HM, Williams MA. What is a barrier to entry? Am Econ Rev. 2004;94(2):461–465.
Chen Y, Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev. 2012;64(7): 640–665.
Behnke N, Retterath M, Sangster T, Singh A. New paths to value creation in pharma. Bain Br. http://www.bain.com/publications/articles/new-paths-to-value-creation-in-pharma.aspx. Published 2014. Accessed March 19, 2018.
Edwards NV. Pharmaceutical new product development: the increasing role of in-licensing. Anesthesiol Clin. 2008;26(4): 627–636.
Sahaf MA. Strategic Marketing: Making Decisions for Strategic Advantage. New Delhi, India: Prentice-Hall India; 2008.
Hagedoorn J, Schakenraad J. The effect of strategic technology alliances on company performance. Strategic Manag J. 1994;15: 291–309.
Gillen JE, Tse T, Ide NC. Design, implementation and management of a web-based data entry system for ClinicalTrials.gov. Stud Health Technol Inform. 2004;107(pt 2):1466–1470.
Tasneem A, Aberle L, Ananth H, et al. The database for aggregate analysis of Clinicaltrials.gov (AACT) and subsequent regrouping by clinical specialty. PLoS One. 2012;7(3):e33677.
Sewell W. Medical subject headings in MEDLARS. Bull Med Libr Assoc. 1964;52:164–170.
Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007–2010. JAMA. 2012;307(17):1838–1847.
Step 3: Clinical Research. U.S. Food and Drug Administration Web site. https://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm. Published January 2018. Accessed April 6, 2018.
Orphanet: an online rare disease and orphan drug data base. © INSERM 1997. http://www.orphadata.org. Accessed March 20, 2018.
Hunter J, Stephens S. Is open innovation the way forward for big pharma? Nat Rev Drug Discov. 2010;9:87–88.
Tralau-Stewart CJ, Wyatt CA, Kleyn DE, Ayad A. Drug discovery: new models for industry-academic partnerships. Drug Discov Today. 2009;14(1–2):95–101.
Hammonds T. Academic-pharma drug discovery alliances: seeking ways to eliminate the valley of death. Future Med Chem. 2015;7(14):1891–1899.
Berger J, Dunn JD, Johnson MM, Karst KR, Shear WC. How drug life-cycle management patent strategies may impact formulary management. Am J Manag Care. 2016;22(16)(suppl): S487–S495.
Sachs RE, Ginsburg PB, Goldman DP. Encouraging new uses for old drugs. JAMA. 2017;318(24):2421–2422.
Frail DE, Brady M, Escott KJ, et al. Pioneering government-sponsored drug repositioning collaborations: progress and learning. Nat Rev Drug Discov. 2015;14(12):833–841.
Zarin DA, Tse T. Moving toward transparency of clinical trials. Science. 2008;319(5868):1340–1342.
Yang H, Lee H. Long-term collaboration network based on ClinicalTrials.gov database in the pharmaceutical industry. Sustainability. 2018;10(2):322.
Meekings KN, Williams CSM, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today. 2012;17(13–14):660–664.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Okada, K., Sengoku, S. Entry Into New Therapeutic Areas: The Effect of Alliance on Clinical Trials. Ther Innov Regul Sci 53, 648–653 (2019). https://doi.org/10.1177/2168479018811829
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479018811829